{"shortAnswer":"Tirzepatide is FDA-approved as Mounjaro and Zepbound, with a prescription. The evidence grade is strong-human for blood sugar, weight and sleep apnea. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.","url":"https://peptideindex.ai/compound/tirzepatide","status":"fda-approved","statusCheckedAt":"2026-10-25T06:21:23.526Z","statusStale":false,"regulatoryAsOf":"2026-10-24","verified":"2026-10-25T06:21:23.561Z","primarySourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"61470e11-1ce9-4faa-aab2-88c4a516f540","object":"compound","slug":"tirzepatide","name":"Tirzepatide","attrs":{"name":"Tirzepatide","class":"dual-or-triple-agonist","access":[{"type":"approved-product","detail":"Approved by FDA and sold with a prescription as a weekly shot for type 2 diabetes.","indication":"Type 2 diabetes in adults and children 10 and older, and lower heart risk in adults with type 2 diabetes at high risk.","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","brand_names":["Mounjaro"],"manufacturer":"Eli Lilly and Company"},{"type":"approved-product","detail":"Approved by FDA and sold with a prescription as a weekly shot for weight loss, and for sleep apnea in adults with obesity.","indication":"Weight loss in adults with obesity, or with overweight and a related health problem, and moderate to severe sleep apnea in adults with obesity.","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","brand_names":["Zepbound"],"manufacturer":"Eli Lilly and Company"},{"type":"lawful-compounding","detail":"FDA said the shortage ended on 19 December 2024. A pharmacy may make a version for one patient only when the prescriber writes down why that patient needs a change from the approved drug. Regular copies of the approved drug are not allowed.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"}],"dosing":"From the Mounjaro and Zepbound labels. Both are shots under the skin once a week. Both start at 2.5 mg a week and go up by 2.5 mg after at least 4 weeks. Mounjaro: the most is 15 mg a week for adults and 10 mg a week for children 10 and older. Zepbound: the dose to stay on is 5 mg, 10 mg or 15 mg a week for weight, or 10 mg or 15 mg for sleep apnea, and the most is 15 mg. The prescriber sets the dose.","trials":[{"nct":"NCT07265752","url":"https://clinicaltrials.gov/study/NCT07265752","phase":"Phase 2","title":"Tirzepatide for the Treatment of Cannabis Use Disorder","status":"not-yet-recruiting","sponsor":"Brigham and Women's Hospital","countries":[],"us_states":[]},{"nct":"NCT07847515","url":"https://clinicaltrials.gov/study/NCT07847515","phase":"Not stated","title":"Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients","status":"not-yet-recruiting","sponsor":"Nanjing First Hospital, Nanjing Medical University","countries":["China"],"us_states":[]},{"nct":"NCT07078838","url":"https://clinicaltrials.gov/study/NCT07078838","phase":"Phase 2","title":"Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer","status":"not-yet-recruiting","sponsor":"UNC Lineberger Comprehensive Cancer Center","countries":["United States"],"us_states":["North Carolina"]},{"nct":"NCT07622992","url":"https://clinicaltrials.gov/study/NCT07622992","phase":"Not stated","title":"Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery","status":"not-yet-recruiting","sponsor":"Mario Musella MD","countries":["Italy"],"us_states":[]},{"nct":"NCT07829198","url":"https://clinicaltrials.gov/study/NCT07829198","phase":"Phase 3","title":"Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","status":"not-yet-recruiting","sponsor":"Universidade do Porto","countries":["Portugal"],"us_states":[]},{"nct":"NCT07787936","url":"https://clinicaltrials.gov/study/NCT07787936","phase":"Not stated","title":"GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry","status":"not-yet-recruiting","sponsor":"Miedziowe Centrum Zdrowia SA","countries":["Poland"],"us_states":[]},{"nct":"NCT07881432","url":"https://clinicaltrials.gov/study/NCT07881432","phase":"Phase 3","title":"A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes","status":"not-yet-recruiting","sponsor":"Eli Lilly and Company","countries":["United States","Argentina","China","Germany","India","Japan","Puerto Rico","South Korea","United Kingdom"],"us_states":["Arizona","California","Connecticut","Florida","Georgia","Hawaii","Illinois","Indiana","Louisiana","Maryland","Massachusetts","Mississippi","Nevada","New Mexico","New York","North Carolina","Pennsylvania","Tennessee","Texas","Utah","Virginia"]},{"nct":"NCT06180616","url":"https://clinicaltrials.gov/study/NCT06180616","phase":"Phase 2","title":"Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity","status":"not-yet-recruiting","sponsor":"Royal North Shore Hospital","countries":[],"us_states":[]},{"nct":"NCT07889648","url":"https://clinicaltrials.gov/study/NCT07889648","phase":"Phase 3","title":"A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications","status":"not-yet-recruiting","sponsor":"Hoffmann-La Roche","countries":[],"us_states":[]},{"nct":"NCT07468552","url":"https://clinicaltrials.gov/study/NCT07468552","phase":"Phase 2","title":"Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","status":"not-yet-recruiting","sponsor":"National Institute on Drug Abuse (NIDA)","countries":[],"us_states":[]},{"nct":"NCT07855900","url":"https://clinicaltrials.gov/study/NCT07855900","phase":"Phase 3","title":"SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight","status":"not-yet-recruiting","sponsor":"Boehringer Ingelheim","countries":["United States"],"us_states":["Florida"]},{"nct":"NCT07796477","url":"https://clinicaltrials.gov/study/NCT07796477","phase":"Phase 2","title":"A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin","status":"not-yet-recruiting","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","countries":["China"],"us_states":[]},{"nct":"NCT07099742","url":"https://clinicaltrials.gov/study/NCT07099742","phase":"Not stated","title":"Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)","status":"not-yet-recruiting","sponsor":"Dr. Md. Alimur Reza","countries":["Bangladesh"],"us_states":[]},{"nct":"NCT07881458","url":"https://clinicaltrials.gov/study/NCT07881458","phase":"Phase 3","title":"A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes","status":"not-yet-recruiting","sponsor":"Eli Lilly and Company","countries":["United States","Brazil","China","Germany","Japan","Puerto Rico","Romania","South Korea","Spain","Taiwan"],"us_states":["Arizona","California","Colorado","Florida","Georgia","Hawaii","Indiana","Louisiana","Missouri","New Jersey","New York","Texas","Virginia","Washington"]},{"nct":"NCT07878494","url":"https://clinicaltrials.gov/study/NCT07878494","phase":"Not applicable","title":"Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia","status":"not-yet-recruiting","sponsor":"Stanford University","countries":["United States"],"us_states":["California"]},{"nct":"NCT07349641","url":"https://clinicaltrials.gov/study/NCT07349641","phase":"Phase 2","title":"A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer","status":"not-yet-recruiting","sponsor":"National Cancer Institute (NCI)","countries":["United States"],"us_states":["Illinois","Texas"]},{"nct":"NCT07609160","url":"https://clinicaltrials.gov/study/NCT07609160","phase":"Not applicable","title":"Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals","status":"not-yet-recruiting","sponsor":"Acibadem University","countries":[],"us_states":[]},{"nct":"NCT07832084","url":"https://clinicaltrials.gov/study/NCT07832084","phase":"Phase 4","title":"Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s","status":"not-yet-recruiting","sponsor":"Jing Luo","countries":["United States"],"us_states":["Pennsylvania"]},{"nct":"NCT07812636","url":"https://clinicaltrials.gov/study/NCT07812636","phase":"Early phase 1","title":"Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer","status":"not-yet-recruiting","sponsor":"Milton S. Hershey Medical Center","countries":["United States"],"us_states":["Pennsylvania"]},{"nct":"NCT07027969","url":"https://clinicaltrials.gov/study/NCT07027969","phase":"Phase 4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"not-yet-recruiting","sponsor":"Ali Aminian","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07881783","url":"https://clinicaltrials.gov/study/NCT07881783","phase":"Not stated","title":"A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy","status":"not-yet-recruiting","sponsor":"Novartis Pharmaceuticals","countries":[],"us_states":[]},{"nct":"NCT07874828","url":"https://clinicaltrials.gov/study/NCT07874828","phase":"Phase 2","title":"PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study","status":"recruiting","sponsor":"M.D. Anderson Cancer Center","countries":["United States"],"us_states":["Texas"]},{"nct":"NCT07868354","url":"https://clinicaltrials.gov/study/NCT07868354","phase":"Phase 1","title":"A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication","status":"recruiting","sponsor":"Novo Nordisk A/S","countries":["United States"],"us_states":["California","Maryland"]},{"nct":"NCT07777575","url":"https://clinicaltrials.gov/study/NCT07777575","phase":"Phase 4","title":"Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide","status":"recruiting","sponsor":"Technical University of Munich","countries":["Germany"],"us_states":[]},{"nct":"NCT07758231","url":"https://clinicaltrials.gov/study/NCT07758231","phase":"Phase 1","title":"Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics","status":"not-yet-recruiting","sponsor":"University of Wisconsin, Madison","countries":["United States"],"us_states":["Wisconsin"]},{"nct":"NCT07809568","url":"https://clinicaltrials.gov/study/NCT07809568","phase":"Not stated","title":"Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes","status":"not-yet-recruiting","sponsor":"Universiti Sains Malaysia","countries":["Pakistan"],"us_states":[]},{"nct":"NCT07825857","url":"https://clinicaltrials.gov/study/NCT07825857","phase":"Phase 2","title":"Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder","status":"not-yet-recruiting","sponsor":"University of Texas Southwestern Medical Center","countries":["United States"],"us_states":["California","Oklahoma","Texas"]},{"nct":"NCT07782359","url":"https://clinicaltrials.gov/study/NCT07782359","phase":"Phase 1","title":"Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib","status":"not-yet-recruiting","sponsor":"University of Chicago","countries":["United States"],"us_states":["Illinois"]},{"nct":"NCT07846865","url":"https://clinicaltrials.gov/study/NCT07846865","phase":"Phase 2/Phase 3","title":"Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial","status":"not-yet-recruiting","sponsor":"Woolcock Institute of Medical Research","countries":["Australia"],"us_states":[]},{"nct":"NCT07387796","url":"https://clinicaltrials.gov/study/NCT07387796","phase":"Not applicable","title":"Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","status":"recruiting","sponsor":"The University of Texas at Dallas","countries":["United States"],"us_states":["Texas"]},{"nct":"NCT07845500","url":"https://clinicaltrials.gov/study/NCT07845500","phase":"Phase 3","title":"A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity","status":"recruiting","sponsor":"Pfizer","countries":["United States"],"us_states":["Alabama","California","Florida","Kentucky","Michigan","Mississippi","Missouri","Montana","North Carolina","Ohio","South Carolina"]},{"nct":"NCT07817875","url":"https://clinicaltrials.gov/study/NCT07817875","phase":"Phase 3","title":"Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)","status":"recruiting","sponsor":"Eli Lilly and Company","countries":["United States","Belgium","Israel","Italy","Mexico","Poland","Portugal","South Korea","Spain","Taiwan"],"us_states":["Arizona","California","Colorado","Connecticut","Florida","Georgia","Illinois","Indiana","Kentucky","Maryland","Massachusetts","Michigan","Minnesota","Nebraska","New York","North Carolina","Ohio","Oklahoma","South Carolina","Tennessee","Texas","Virginia","Washington"]},{"nct":"NCT07846956","url":"https://clinicaltrials.gov/study/NCT07846956","phase":"Not stated","title":"NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study","status":"not-yet-recruiting","sponsor":"Istanbul Saglik Bilimleri University","countries":["Turkey (Türkiye)"],"us_states":[]},{"nct":"NCT07734792","url":"https://clinicaltrials.gov/study/NCT07734792","phase":"Phase 2/Phase 3","title":"Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial","status":"not-yet-recruiting","sponsor":"yifang zhu","countries":["China"],"us_states":[]},{"nct":"NCT07734870","url":"https://clinicaltrials.gov/study/NCT07734870","phase":"Phase 2","title":"Tirzepatide for Treatment of CCCA","status":"recruiting","sponsor":"Johns Hopkins University","countries":["United States"],"us_states":["Maryland"]},{"nct":"NCT07803744","url":"https://clinicaltrials.gov/study/NCT07803744","phase":"Phase 1","title":"A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity","status":"recruiting","sponsor":"Eli Lilly and Company","countries":["United States"],"us_states":["Florida"]},{"nct":"NCT07715929","url":"https://clinicaltrials.gov/study/NCT07715929","phase":"Phase 4","title":"Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients","status":"not-yet-recruiting","sponsor":"Yunlong Wang","countries":[],"us_states":[]},{"nct":"NCT07728812","url":"https://clinicaltrials.gov/study/NCT07728812","phase":"Not applicable","title":"Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy","status":"not-yet-recruiting","sponsor":"Phenomix Sciences","countries":[],"us_states":[]},{"nct":"NCT07811895","url":"https://clinicaltrials.gov/study/NCT07811895","phase":"Not applicable","title":"Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer","status":"not-yet-recruiting","sponsor":"RenJi Hospital","countries":["China"],"us_states":[]},{"nct":"NCT07756359","url":"https://clinicaltrials.gov/study/NCT07756359","phase":"Phase 4","title":"Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)","status":"not-yet-recruiting","sponsor":"University of North Carolina, Chapel Hill","countries":["United States"],"us_states":["California","Minnesota","Missouri","North Carolina","Utah"]},{"nct":"NCT07747805","url":"https://clinicaltrials.gov/study/NCT07747805","phase":"Phase 2","title":"GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","status":"not-yet-recruiting","sponsor":"The Cleveland Clinic","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07842640","url":"https://clinicaltrials.gov/study/NCT07842640","phase":"Phase 1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight","status":"recruiting","sponsor":"Ascletis Pharma (China) Co., Limited","countries":["United States"],"us_states":["Maryland"]},{"nct":"NCT07191873","url":"https://clinicaltrials.gov/study/NCT07191873","phase":"Phase 4","title":"Tirzepatide in Idiopathic Intracranial Hypertension Trial","status":"recruiting","sponsor":"Duke University","countries":["United States"],"us_states":["North Carolina"]},{"nct":"NCT07720466","url":"https://clinicaltrials.gov/study/NCT07720466","phase":"Not stated","title":"Salivary Function and Dental Changes During GLP-1 Therapy","status":"not-yet-recruiting","sponsor":"Bilecik Seyh Edebali Universitesi","countries":["Turkey (Türkiye)"],"us_states":[]},{"nct":"NCT06732245","url":"https://clinicaltrials.gov/study/NCT06732245","phase":"Phase 2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"not-yet-recruiting","sponsor":"Biomed Industries, Inc.","countries":["United States","Australia","New Zealand"],"us_states":["California","Florida","New York","Texas"]},{"nct":"NCT07728318","url":"https://clinicaltrials.gov/study/NCT07728318","phase":"Not applicable","title":"Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients","status":"not-yet-recruiting","sponsor":"Akhtar Saeed Medical and Dental College","countries":[],"us_states":[]},{"nct":"NCT07760532","url":"https://clinicaltrials.gov/study/NCT07760532","phase":"Not stated","title":"Comparing Facial Aging Between Identical Twins With 3D Imaging","status":"not-yet-recruiting","sponsor":"Ponsky Facial Aesthetics And Plastic Surgery, Llc","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07554638","url":"https://clinicaltrials.gov/study/NCT07554638","phase":"Phase 4","title":"Incretin Therapies in Obesity-related HFpEF","status":"recruiting","sponsor":"Columbia University","countries":["United States"],"us_states":["New York"]},{"nct":"NCT07213323","url":"https://clinicaltrials.gov/study/NCT07213323","phase":"Not applicable","title":"Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment","status":"recruiting","sponsor":"Hospices Civils de Lyon","countries":["France"],"us_states":[]},{"nct":"NCT07671248","url":"https://clinicaltrials.gov/study/NCT07671248","phase":"Phase 3","title":"Tirzepatide in the Treatment of Cannabis Use Disorder","status":"not-yet-recruiting","sponsor":"McMaster University","countries":["Canada"],"us_states":[]}],"aliases":["Mounjaro","Zepbound"],"summary":"A prescription drug that acts on the body's receptors for two hormones, GIP and GLP-1. FDA approved it as Mounjaro for diabetes and as Zepbound for weight loss.","citations":[{"n":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","tier":"primary","type":"regulatory","title":"Drugs@FDA: Mounjaro injection, application 215866"},{"n":2,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806","tier":"primary","type":"regulatory","title":"Drugs@FDA: Zepbound injection, application 217806"},{"n":3,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","tier":"primary","type":"label","title":"DailyMed: Mounjaro injection prescribing information, revised August 2026"},{"n":4,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","tier":"primary","type":"label","title":"DailyMed: Zepbound injection prescribing information, revised August 2026"},{"n":5,"url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r","tier":"primary","type":"regulatory","title":"FDA drug shortages: tirzepatide injection, resolved"},{"n":6,"url":"https://www.fda.gov/media/184606/download","tier":"primary","type":"regulatory","title":"FDA order: the tirzepatide injection shortage is resolved, 19 December 2024"},{"n":7,"url":"https://www.fda.gov/media/185577/download","tier":"primary","type":"regulatory","title":"FDA memo: resolution of the tirzepatide injection shortage, 19 December 2024"},{"n":8,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize","tier":"primary","type":"regulatory","title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026"},{"n":9,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","tier":"primary","type":"regulatory","title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026"},{"n":10,"url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list","tier":"primary","type":"regulatory","title":"FDA: proposal to exclude tirzepatide from the 503B bulks list, 30 April 2026"},{"n":11,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026","tier":"primary","type":"regulatory","title":"FDA warning letter to a website offering compounded tirzepatide, 8 June 2026"},{"n":12,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026","tier":"primary","type":"regulatory","title":"FDA warning letter to an online seller of research-use peptides, 31 March 2026"},{"n":13,"url":"https://www.mcdermottlaw.com/insights/court-backs-fda-in-tirzepatide-compounding-case/","tier":"legal-analysis","type":"legal-analysis","title":"McDermott Will & Schulte: court backs FDA in the tirzepatide compounding case"},{"n":14,"url":"https://www.frierlevitt.com/articles/fda-determines-again-the-tirzepatide-shortage-is-resolved-what-this-means-for-503a-and-503b-compounding","tier":"legal-analysis","type":"legal-analysis","title":"Frier Levitt: FDA again finds the tirzepatide shortage resolved"},{"n":15,"url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs","tier":"legal-analysis","type":"legal-analysis","title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/34186022/","tier":"peer-reviewed","type":"rct","title":"SURPASS-1: tirzepatide alone in type 2 diabetes, 2021"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/34170647/","tier":"peer-reviewed","type":"rct","title":"SURPASS-2: tirzepatide versus semaglutide in type 2 diabetes, 2021"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","tier":"peer-reviewed","type":"rct","title":"SURMOUNT-1: weekly tirzepatide in adults with obesity, 2022"},{"n":19,"url":"https://pubmed.ncbi.nlm.nih.gov/38912654/","tier":"peer-reviewed","type":"rct","title":"SURMOUNT-OSA: tirzepatide for sleep apnea in adults with obesity, 2024"},{"n":20,"url":"https://pubmed.ncbi.nlm.nih.gov/41406444/","tier":"peer-reviewed","type":"rct","title":"SURPASS-CVOT: tirzepatide versus dulaglutide and heart outcomes, 2025"},{"n":21,"url":"https://pubmed.ncbi.nlm.nih.gov/37253796/","tier":"peer-reviewed","type":"systematic-review","title":"Review and meta-analysis of tirzepatide for weight loss, 2023"},{"n":22,"url":"https://pubmed.ncbi.nlm.nih.gov/37908750/","tier":"peer-reviewed","type":"systematic-review","title":"Review of pancreas and gallbladder safety with tirzepatide, 2023"},{"n":23,"url":"https://www.nbcnews.com/health/health-news/fda-says-eli-lilly-weight-loss-drug-shortage-taking-second-look-rcna184842","tier":"established-news","type":"reference","title":"NBC News: FDA says the tirzepatide shortage is over after a second look"}],"known_risks":["In rats, tirzepatide caused thyroid tumors. The labels warn people with a rare thyroid cancer in the family not to use it [^3] [^4].","The most common problems are nausea, diarrhea, vomiting, constipation and belly pain [^3] [^4]. In the main weight trial, more people on it than on a dummy shot stopped because of unwanted effects [^18].","The labels warn of a swollen pancreas, gallbladder disease, kidney harm from losing fluids, and bad allergic reactions [^3] [^4]. A 2023 review of nine trials found more gallbladder and bile duct problems than with a dummy shot or insulin [^22].","Taken with insulin or some other diabetes drugs, it can push blood sugar too low [^3] [^4].","It slows how fast the stomach empties, so birth control pills may work less well. The labels advise adding another method for 4 weeks after starting and after each dose increase [^3] [^4].","FDA has more than 730 reports of harm tied to compounded tirzepatide. Some people were given more than the label allows [^9]."],"short_answer":"Tirzepatide is FDA-approved as Mounjaro and Zepbound, with a prescription. The evidence grade is strong-human for blood sugar, weight and sleep apnea. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.","evidence_grade":"strong-human","open_questions":["Nobody knows if it can cause thyroid cancer in people. The rat studies do not tell us [^3].","The main weight trial lasted 72 weeks, so it does not show what many years of use do [^18].","A 2023 review found no clear rise in a swollen pancreas. The range of possible effects was wide, so the question is open [^22].","In a large heart trial, it did about as well as an older drug, dulaglutide. The trial did not show that it lowers heart risk more [^20].","Nobody knows how closely pharmacy copies match the approved drug. FDA does not review them for safety, quality or whether they work [^9]."],"section_routes":"The legal way to get tirzepatide is a prescription for Mounjaro or Zepbound, filled at a state-licensed pharmacy [^1] [^2] [^9]. Both are approved by FDA [^1] [^2]. Each label says who it is for and how it is taken [^3] [^4].\n\nA copy made by a pharmacy is lawful only in narrow cases. The prescriber has to write down why one patient needs a change from the approved drug, such as an allergy to one of its parts [^8] [^15]. FDA says pharmacy copies should be used only when an approved drug cannot meet a patient's needs [^9]. FDA does not check pharmacy copies for safety, quality or whether they work [^9]. Outsourcing facilities may not make it from raw powder, because it is on neither the shortage list nor their list of allowed ingredients [^8] [^15].","regulatory_as_of":"2026-10-24","section_channels":"Tirzepatide reaches people outside the approved brands in four main ways [^9]. The first is pharmacies that kept making copies after the shortage ended [^8] [^13]. FDA has more than 730 reports of harm tied to pharmacy copies. It says many more likely go unreported [^9]. The second is websites that offer these copies. FDA has warned a site whose claims suggested a copy was approved [^11]. The third is fake products. FDA has found copies with labels naming pharmacies that do not exist or did not make them [^9]. The fourth is online sellers that label it for research use. FDA has warned such a seller that the label does not make the sale legal [^12].\n\nIn each case, FDA cannot vouch for what is in the product [^9]. Some people were given more than the approved label allows and needed medical care [^9]. Shots shipped without enough cold packs may lose quality [^9].","section_evidence":"The evidence grade is strong-human: several large trials in people agree that it lowers blood sugar and weight [^16] [^17] [^18]. In a 40-week trial of 478 adults with type 2 diabetes, it lowered blood sugar far more than a dummy shot [^16]. In a 40-week trial of 1,879 adults with type 2 diabetes, it lowered blood sugar and weight more than semaglutide [^17]. In a 72-week trial of 2,539 adults with obesity and no diabetes, people on it lost 15% to 21% of their weight. People on the dummy shot lost about 3% [^18]. In two 52-week trials of adults with obesity and sleep apnea, it cut breathing pauses during sleep far more than a dummy shot [^19]. A 2023 review of trials with 5,800 people found that most lost at least 5% of their weight [^21].\n\nIn a heart trial of 13,299 adults with type 2 diabetes and heart disease, it was compared with dulaglutide, an older drug. Heart attacks, strokes and heart deaths were about as common with both. Tirzepatide was not worse, but it was not shown to be better [^20].\n\nThese trials tested the approved drug from its maker, and the maker paid for them [^16] [^17] [^18] [^19] [^20]. They tell us nothing about copies made by pharmacies or sold for research use. FDA has not checked those copies for quality [^9].","regulatory_status":"fda-approved","section_what_it_is":"Tirzepatide is a prescription drug. It copies two hormones, GIP and GLP-1, that the gut makes after you eat [^3]. They help control blood sugar, and tirzepatide also cuts how much people eat [^3]. FDA first approved it in 2022 [^1]. One company makes it and sells it under two brand names [^1] [^2].\n\nMounjaro is a weekly shot for type 2 diabetes [^3]. Zepbound is a weekly shot for weight loss. It is also for sleep apnea, where breathing stops and starts during sleep, in adults with obesity [^4]. The body clears half of a dose in about 5 days [^3]. That is why the shots are taken once a week.\n\nSome pharmacies and online sellers offer their own copies of it. Those copies are not the approved drug [^9].","section_is_it_legal":"Tirzepatide is FDA-approved: FDA approved it as Mounjaro in May 2022 and as Zepbound in November 2023 [^1] [^2]. That covers the brand drugs, with a prescription, for the uses on their labels. It does not make copies from pharmacies or online sellers approved [^9]. Checked 24 October 2026.\n\nMounjaro is approved for type 2 diabetes, not for weight loss. Zepbound is the brand approved for weight loss [^3] [^4]. Many copies are sold for weight loss [^9] [^11].\n\nIn December 2022 the shots went on FDA's drug shortage list [^6]. During a shortage, pharmacies may make copies of a drug. FDA said the shortage was over in October 2024. A trade group sued, and FDA looked at it again [^6] [^23]. On 19 December 2024, FDA said again that the shortage was over [^5] [^6] [^7]. Pharmacies had until 18 February 2025 to stop making copies. Larger outsourcing facilities had until 19 March 2025 [^6] [^8] [^14]. A court upheld FDA's decision in May 2025 [^13].\n\nToday a pharmacy may not make copies of the approved drug as a regular practice [^8]. It may make a different version for one patient. The prescriber has to write down why that patient needs the change [^8] [^15]. FDA says it will not act on four or fewer copy prescriptions a month [^8]. In April 2026, FDA proposed keeping outsourcing facilities from making it from raw powder. The proposal is not final [^10] [^15]. Selling it with a research-use label is illegal [^12].","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"Copies of the approved shots made by pharmacies and outsourcing facilities, often sent in vials that hold several doses.","enforcement":[{"date":"2024-12-19","text":"FDA said again that the tirzepatide shortage was over, and set end dates in 2025 for pharmacies and outsourcing facilities making copies.","source_url":"https://www.fda.gov/media/184606/download"},{"date":"2026-04-30","text":"FDA proposed keeping tirzepatide off the list of bulk ingredients outsourcing facilities may use. The proposal is not final.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"}],"legal_position":{"text":"Since the shortage ended, a pharmacy may not make copies of the approved drug as a regular practice. Outsourcing facilities may not make it from raw powder, since it is on neither the shortage list nor their list of allowed ingredients.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},"documented_risks":[{"text":"FDA has more than 730 reports of harm tied to compounded tirzepatide, and says many more likely go unreported.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA has reports of harm in people given compounded tirzepatide above the approved label. Some sought care for vomiting, diarrhea and belly pain.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA warns that vials holding several doses carry a higher risk of germs 28 days after first use.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"telehealth","what_it_is":"Websites that offer compounded tirzepatide straight to consumers.","enforcement":[{"date":"2026-06-08","text":"FDA warning letter to a website offering compounded tirzepatide, for claims that suggested the copies were approved.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"}],"legal_position":{"text":"FDA says a site may not suggest a compounded copy is FDA-approved or has been checked for safety and effectiveness.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"},"documented_risks":[{"text":"FDA warns of sites that claim a copy is the same as the approved drug, or send medicine that looks different or lacks instructions.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA has complaints that compounded GLP-1 drugs arrived warm, which can harm their quality.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"counterfeit-or-diverted","what_it_is":"Fake compounded tirzepatide whose label names a pharmacy that does not exist or did not make it.","legal_position":{"text":"FDA calls these drugs illegally marketed and has sent warning letters to stop their sale.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},"documented_risks":[{"text":"FDA has one report of redness, swelling and pain where a person injected a product with a false pharmacy label.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"Drugs sold illegally online may hold the wrong ingredient, too much or too little drug, or none at all, FDA warns.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"research-use-seller","what_it_is":"Sold online with a label saying it is for research use or not for people.","enforcement":[{"date":"2026-03-31","text":"FDA warning letter to an online seller of research-use peptides, including tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"}],"legal_position":{"text":"FDA treats these as unapproved new drugs when the seller's site shows they are meant for people, whatever the label says.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"},"documented_risks":[{"text":"FDA says nobody can be sure of the quality of these products, and they may harm health.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA warns that injected products skip some of the body's defenses, so toxins or germs in them can cause life-threatening illness.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"}]}]},"provenance":{"name":{"fact_id":"5889c53b-5ae2-409e-bcfe-5cbe9a6a5e22","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.540Z","confidence":1,"stale":false},"class":{"fact_id":"f155d1fc-7e2b-4eeb-9b78-4ad72b4436bd","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.543Z","confidence":1,"stale":false},"access":{"fact_id":"ac813973-e079-4516-a516-86aa3c76e567","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","source_type":"primary","captured_at":"2026-10-25T00:12:40.137Z","checked_at":"2026-10-25T06:21:23.511Z","confidence":1,"stale":false},"dosing":{"fact_id":"98fc4ad7-5a5a-4964-8310-8fbed1c0b07e","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.561Z","confidence":1,"stale":false},"trials":{"fact_id":"bf946600-33a7-4007-b07d-d5a4cb37ce87","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=tirzepatide+OR+Mounjaro+OR+Zepbound&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-25T18:03:19.456Z","checked_at":"2026-10-25T18:03:19.456Z","confidence":1,"stale":false},"aliases":{"fact_id":"6f8e339d-f193-486b-9812-1837f6ebf743","source_url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs","source_type":"legal-analysis","captured_at":"2026-10-24T04:24:25.086Z","checked_at":"2026-10-25T06:21:23.542Z","confidence":1,"stale":false},"summary":{"fact_id":"47921980-e155-46c2-9e6f-b63dfa5f4b70","source_url":"https://www.fda.gov/media/184606/download","source_type":"primary","captured_at":"2026-10-25T00:13:36.003Z","checked_at":"2026-10-25T06:21:23.529Z","confidence":1,"stale":false},"citations":{"fact_id":"cc4056f0-1846-4332-b7d9-e5fbaa0f8d97","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.522Z","confidence":1,"stale":false},"known_risks":{"fact_id":"c9a1de0a-e73e-4c40-9951-b9a0b2b7c693","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.549Z","confidence":1,"stale":false},"short_answer":{"fact_id":"7bc3cad4-88f0-4592-acf9-c792f4e43096","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-25T06:21:23.545Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"16d61e48-6733-4ab3-969d-10b96dc3697d","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-25T06:21:23.548Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"efd452e5-3c6b-4acc-88b7-4d59c735e423","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.551Z","confidence":1,"stale":false},"section_routes":{"fact_id":"37efa323-cab4-4f54-8234-407a8b56b964","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","source_type":"primary","captured_at":"2026-10-25T00:12:40.137Z","checked_at":"2026-10-25T06:21:23.556Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"4fa7b9e6-116f-4674-9b62-1ee6c5dfc660","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","source_type":"primary","captured_at":"2026-10-25T00:12:40.137Z","checked_at":"2026-10-25T06:21:23.546Z","confidence":1,"stale":false},"section_channels":{"fact_id":"2f398847-32c4-489a-9322-58cf4e6c7437","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-25T06:21:23.558Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"2daa3242-4687-4aff-a4db-efa4b52cea3f","source_url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","source_type":"peer-reviewed","captured_at":"2026-10-25T00:13:39.045Z","checked_at":"2026-10-25T06:21:23.554Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"c1ebe3f2-65f0-498c-99f7-6322bbb91b72","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806","source_type":"primary","captured_at":"2026-10-25T00:12:40.239Z","checked_at":"2026-10-25T06:21:23.526Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"a14ffa28-6c79-45ba-8241-ab01336cdf12","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","source_type":"primary","captured_at":"2026-10-25T00:12:39.733Z","checked_at":"2026-10-25T06:21:23.552Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"f52d4ee5-f617-495f-a9bf-319c5df3a573","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","source_type":"primary","captured_at":"2026-10-25T00:12:40.137Z","checked_at":"2026-10-25T06:21:23.553Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"7ee71113-b4e9-4f5c-a659-3bee5efcfede","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-25T06:21:23.537Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":3,"title":"DailyMed: Mounjaro injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"n":4,"title":"DailyMed: Zepbound injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b"},{"n":18,"title":"SURMOUNT-1: weekly tirzepatide in adults with obesity, 2022","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/"},{"n":22,"title":"Review of pancreas and gallbladder safety with tirzepatide, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37908750/"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"open_questions":[{"n":3,"title":"DailyMed: Mounjaro injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"n":18,"title":"SURMOUNT-1: weekly tirzepatide in adults with obesity, 2022","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/"},{"n":22,"title":"Review of pancreas and gallbladder safety with tirzepatide, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37908750/"},{"n":20,"title":"SURPASS-CVOT: tirzepatide versus dulaglutide and heart outcomes, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/41406444/"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_routes":[{"n":1,"title":"Drugs@FDA: Mounjaro injection, application 215866","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866"},{"n":2,"title":"Drugs@FDA: Zepbound injection, application 217806","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":3,"title":"DailyMed: Mounjaro injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"n":4,"title":"DailyMed: Zepbound injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b"},{"n":8,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":15,"title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs","url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"}],"section_channels":[{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":8,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":13,"title":"McDermott Will & Schulte: court backs FDA in the tirzepatide compounding case","url":"https://www.mcdermottlaw.com/insights/court-backs-fda-in-tirzepatide-compounding-case/"},{"n":11,"title":"FDA warning letter to a website offering compounded tirzepatide, 8 June 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"},{"n":12,"title":"FDA warning letter to an online seller of research-use peptides, 31 March 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"}],"section_evidence":[{"n":16,"title":"SURPASS-1: tirzepatide alone in type 2 diabetes, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/34186022/"},{"n":17,"title":"SURPASS-2: tirzepatide versus semaglutide in type 2 diabetes, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/34170647/"},{"n":18,"title":"SURMOUNT-1: weekly tirzepatide in adults with obesity, 2022","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/"},{"n":19,"title":"SURMOUNT-OSA: tirzepatide for sleep apnea in adults with obesity, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38912654/"},{"n":21,"title":"Review and meta-analysis of tirzepatide for weight loss, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37253796/"},{"n":20,"title":"SURPASS-CVOT: tirzepatide versus dulaglutide and heart outcomes, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/41406444/"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_what_it_is":[{"n":3,"title":"DailyMed: Mounjaro injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"n":1,"title":"Drugs@FDA: Mounjaro injection, application 215866","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866"},{"n":2,"title":"Drugs@FDA: Zepbound injection, application 217806","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806"},{"n":4,"title":"DailyMed: Zepbound injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_is_it_legal":[{"n":1,"title":"Drugs@FDA: Mounjaro injection, application 215866","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866"},{"n":2,"title":"Drugs@FDA: Zepbound injection, application 217806","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806"},{"n":9,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":3,"title":"DailyMed: Mounjaro injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"n":4,"title":"DailyMed: Zepbound injection prescribing information, revised August 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b"},{"n":11,"title":"FDA warning letter to a website offering compounded tirzepatide, 8 June 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026"},{"n":6,"title":"FDA order: the tirzepatide injection shortage is resolved, 19 December 2024","url":"https://www.fda.gov/media/184606/download"},{"n":23,"title":"NBC News: FDA says the tirzepatide shortage is over after a second look","url":"https://www.nbcnews.com/health/health-news/fda-says-eli-lilly-weight-loss-drug-shortage-taking-second-look-rcna184842"},{"n":5,"title":"FDA drug shortages: tirzepatide injection, resolved","url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r"},{"n":7,"title":"FDA memo: resolution of the tirzepatide injection shortage, 19 December 2024","url":"https://www.fda.gov/media/185577/download"},{"n":8,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":14,"title":"Frier Levitt: FDA again finds the tirzepatide shortage resolved","url":"https://www.frierlevitt.com/articles/fda-determines-again-the-tirzepatide-shortage-is-resolved-what-this-means-for-503a-and-503b-compounding"},{"n":13,"title":"McDermott Will & Schulte: court backs FDA in the tirzepatide compounding case","url":"https://www.mcdermottlaw.com/insights/court-backs-fda-in-tirzepatide-compounding-case/"},{"n":15,"title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs","url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"},{"n":10,"title":"FDA: proposal to exclude tirzepatide from the 503B bulks list, 30 April 2026","url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"},{"n":12,"title":"FDA warning letter to an online seller of research-use peptides, 31 March 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=tirzepatide+OR+Mounjaro+OR+Zepbound&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/35658024/","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806","https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","https://www.fda.gov/media/184606/download","https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"],"verified_at":"2026-10-25T06:21:23.561Z","published_at":"2026-10-25T18:23:23.091Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-25T18:03:19.456Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}